K-Nor Powder for Suspension

Calcium Polystyrene Sulfonate acts by a cumulative process throughout the gastrointestinal tract, removing potassium ions which are excreted in the feces. Calcium Polystyrene Sulfonate passes through the colon and comes into contact with fluids containing increased amounts of potassium. The result is that potassium is taken up in increasing amounts in exchange for calcium ions. The length of time Calcium Polystyrene Sulfonate remains in the body is a decisive factor in its effectiveness. For this reason oral administration is more effective than rectal administration.

Calcium Polystyrene Sulfonate is for oral or rectal administration only. Treatment with the resin should be given as soon as the serum potassium level rises above 6 mmol/L.

Adults (Including the Elderly)-

• Oral: For adults the usual dose is 15 g, 3 or 4 times a day. The resin is given by mouth as a suspension in a little water or for greater palatability, the resin may be made into a paste with some sweetened vehicle but not orange juice or other fruit juices that are known to contain potassium. The amount of fluid usually ranges from 3 to 4 ml for per gram of resin.
• Rectal: In cases where oral administration is not possible Calcium Polystyrene Sulfonate may be given rectally as a suspension of 30 g resin in 100 ml of 2% methylcellulose and 100 ml of water as a daily retention enema.

Pediatrics-

• Oral: Children should be given 1 g/kg body weight of Calcium Polystyrene Sulfonate daily in divided doses in acute hyperkalemia. In maintenance therapy the dose may be reduced to 0.5 g/kg body weight daily in divided doses.
• Rectal: It can be given rectally suspended in a proportional amount of 10% dextrose in water. Following retention of the enema, the colon should be irrigated to ensure adequate removal of the resin.

Neonates-

• Oral administration of Calcium Polystyrene Sulfonate is contraindicated in neonates.
• Only rectal administration should be considered. With rectal administration, the minimum effective dosage within the range of 0.5 g/kg to 1 g/kg should be given diluted as for adults and with adequate irrigation to ensure recovery of the resin.

Concomitant use of K-Nor is not recommended with Sorbitol, Digitalis drugs, Cation donating agents, Non-absorbable cation-donating antacids and laxatives, Aluminum hydroxide, Lithium, Thyroxine.

Calcium Polystyrene Sulfonate should not be administered to patients with Serum potassium <5 mmol/L and a conditions associated with hypercalcemia, hyperparathyroidism, multiple myeloma, sarcoidosis or metastic carcinoma, history of hypersensitivity to polystyrene sulfonate resins and obstructive bowel disease. Oral administration of Calcium Polystyrene Sulfonate is contraindicated in neonates.

Nausea, vomiting, gastric irritation, anorexia, constipation and occasionally diarrhea, fecal impaction, Gastrointestinal stenosis and intestinal obstruction, Gastrointestinal ischemia, ischemic colitis, rectal haemorrhage, gastrointestinal tract ulceration or necrosis, Hypomagnesemia, Hypercalcemia etc. Some cases of acute bronchitis and bronchopneumonia have been reported.

Calcium Polystyrene Sulfonate is not absorbed from the gastrointestinal tract. No data are available about the use of this in human pregnancy and lactation.

During treatment with K-Nor the possibility of severe potassium depletion should be considered. To prevent serious hypokalemia, administration of the resin should be discontinued as soon as the serum potassium level falls to 5 mmol/L. Hypomagnesemia and hypercalcemia may occur. Patients should be monitored for all electrolyte disturbances. In the event of clinically significant constipation, treatment with the resin should be discontinued until normal bowel motions are resumed. Magnesium-containing laxatives should not be used. The patient should be positioned carefully when ingesting the resin to avoid aspiration which may lead to bronchopulmonary complications.

Children and neonates: K-Nor should not be given by the oral route. In both children and neonates, particular care should be observed with rectal administration.

Clinical signs and symptoms of hypokalemia including irritability, confusion, delayed thought processes, muscle weakness, hyporeflexia and eventually frank paralysis. Apnea may be a serious consequence of this progression. Electrocardiographic changes may be consistent with hypokalemia or hypercalcemia; cardiac arrhythmia may occur.

Hyperkalaemia Products

Store at below 30°C in a dry place protected from light. Keep out of reach of children.